Renowned Retraction

Authors retract a decade-old, highly-cited cancer study, admitting sloppy mistakes in the data analysis.

By | January 16, 2013

MIT Building 10 and the Great Dome, Cambridge MassachusettsWIKIMEDIA, JOHN PHELANA leading cancer researcher at the Massachusetts Institute of Technology, Robert Weinberg, has retracted a study published in 2003 in Cancer Cell—which has been cited 233 times, according to ISI Web of Knowledge—upon realizing that the study contained careless errors. The authors claim that the retraction is not meant to negate the conclusions of the study, rather it’s meant to purge the literature of the inaccurate data presentation, according to a notice they published on the journal’s website.

“Although we stand by the conclusions of the paper and intend to provide support for them in future publications, the inappropriate presentation did not and does not fall within the bounds of acceptable scienti?c practice,” the authors wrote in the notice. “Accordingly, we are retracting the paper in its entirety.”

The statement also noted that one of the original authors, Yi-Ning Cheng, could not be reached regarding the retraction.

In a statement provided to Retraction Watch, Weinberg elaborated on the publication’s errors, emphasizing that they were not due to misconduct. “These errors occurred during the (electronic) assembly of the figures, with internal loading controls being misassembled with the incorrect experimental channels,” Weinberg said. “There was not and is not any indication of scientific misconduct, simply inadvertent sloppiness in the last minute assembly of these figures.”

Weinberg is one of the most renowned and highly cited cancer researchers in the world, and many of his publications have been cited upwards of 1,000 times.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: Paul Stein

Paul Stein

Posts: 205

January 17, 2013

All of this is simply too strange.  Didn't he proofread the article prior to review and then pre-publication?  Couldn't he have simply corrected the article in a brief letter to the editor?  Why did it take ten years for him to come forward?

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham